Rhenman & Partners Asset Management Invests in Guardant Health

The firm purchased 50,000 shares of the cancer diagnostics company's stock in the third quarter.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB, an investment management firm, purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the third quarter of 2026. The firm acquired 50,000 shares of the company's stock, valued at approximately $3,124,000.

Why it matters

Guardant Health is a leading precision oncology company that develops non-invasive blood tests to detect and profile cancer genomic alterations. Rhenman & Partners' investment in the company suggests they see significant growth potential in Guardant Health's innovative cancer diagnostics technology.

The details

According to the 13F filing with the Securities and Exchange Commission, Rhenman & Partners Asset Management AB purchased 50,000 shares of Guardant Health, Inc. in the third quarter. Guardant Health is a Redwood City, California-based company that specializes in developing liquid biopsy tests to detect cancer mutations from circulating tumor DNA.

  • Rhenman & Partners Asset Management AB purchased the 50,000 shares of Guardant Health in the 3rd quarter of 2026.

The players

Rhenman & Partners Asset Management AB

An investment management firm that purchased a new position in shares of Guardant Health, Inc.

Guardant Health, Inc.

A precision oncology company that develops non-invasive blood tests to detect and profile cancer genomic alterations.

Got photos? Submit your photos here. ›

The takeaway

Rhenman & Partners' investment in Guardant Health underscores the growing interest and potential in the liquid biopsy and cancer diagnostics market, as innovative companies like Guardant Health continue to develop advanced technologies to improve cancer detection and treatment.